Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients.
Children (Basel)
; 10(2)2023 Feb 13.
Article
em En
| MEDLINE
| ID: mdl-36832496
ABSTRACT
INTRODUCTION:
Immunosuppression after pediatric liver transplantation remains a major challenge. MTOR inhibitors provide a promising therapeutic approach in combination with reduced CNI after transplantation. However, there are still few data regarding their use in children. PATIENTS We analyzed 37 patients with a median age of 10 years, who received Everolimus for one or more of the following indications I = chronic graft dysfunction (n = 22); II = progressive renal impairment (n = 5); III = non-tolerable side effects with previous immunosuppressive medication (n = 6); and IV = malignancies (n = 10). The median follow-up time was 36 months.RESULTS:
Patient survival was 97%, and graft survival 84%, respectively. Stabilization of graft function was observed in 59% in subgroup 1, with 18.2% ultimately requiring retransplantation. No patient in subgroup IV developed recurrence of his primary tumor or PTLD by the endpoint of the study. Side effects were observed in 67.5% of the study patients, with infections being the most frequent (n = 20; 54.1%). There were no relevant effects on growth and development.CONCLUSION:
Everolimus seems to be a treatment option in selected pediatric liver graft recipients for whom other regimens are not suitable. Overall, the efficacy was good and the side effect profile appeared to be acceptable.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Children (Basel)
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Alemanha